Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

intain patent protection for its products or product candidates.  Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products.  Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates.  Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

The scientific information discussed in this news release related to Amgen's product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.  Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated.  Further, the scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products.  The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.  Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.CONTACT:AmgenPfizer Christine Regan (media)

Victoria Davis (media)Office: 805-447-5476

Office: 212-733-3227Cell: 617-359-1324

Cell: 347-558-34
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Four studies highlighting late-breaking research advances in the treatment ... at the 50th Annual Meeting of the American Society of ... Results from a study examining the ability of ... the inner lining of blood vessels, in patients with sickle ...
... at ASH Annual Meeting- , , ... announced results of a randomized phase III study presented ... of Hematology. The study in adult patients with hematological ... syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma ...
Cached Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/14/2014)... Carepoint has been designed specifically to facilitate ... intuitive interface for recording, sending, displaying and receiving ... reporting features. , Hall mc - an Ontario-based ... Rebecca de Witte to create this exciting new ... Carepoint provides seamless, real-time communication between the ...
(Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
(Date:7/14/2014)... 2014 Spine Team Texas ... care—from diagnosis to treatment and recovery. Currently all physical ... in or training for certification in The McKenzie Method. ... completed the extensive program. , “We require certification of ... results in better outcomes for spine pain patients,” said ...
(Date:7/14/2014)... July 14, 2014 Cadeon Associates ... Turning Information into Money,” today announced that it ... global program that helps partners resell, deploy, and ... Spotfire® analytics platform. TIBCO Software Inc. is a ... including TIBCO Spotfire analytics, providing businesses the ability ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in the ... multi-colored Quinceanera dresses to its product line. According ... outfits are guaranteed to be quality made. Now, they ... , TopDresses100.com has a wide variety of elegant dresses ... are in stock and ready to ship. As an ...
Breaking Medicine News(10 mins):Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2
... of different alcoholic beverages and drinking behaviour on the risk ... and Cohort of Swedish Men, to study the association between ... acute pancreatitis. In total, 84,601 individuals, aged 46-84 years, ... 513 developed acute pancreatitis. There was a doseresponse association ...
... Aug. 11 (HealthDay News) -- The HIV infection rate among ... of AIDS is 10 to 20 times greater than in ... Two percent of poor heterosexuals in those cities have ... Prevention researchers, analysis of National HIV Behavioral Surveillance System data. ...
... (WASHINGTON, August 11, 2011) According to a study ... of the American Society of Hematology (ASH), researchers ... drug that releases stem cells from the bone marrow into ... at risk for later development of abnormalities involving loss or ...
... THURSDAY, Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s ... 80, according to a new study that examined the ... The study included 105 Alzheimer,s patients and 125 ... 60 to 75 (young-old) and those 80 and older ...
... Mann HealthDay Reporter , WEDNESDAY, Aug. 10 (HealthDay ... people with an irregular heartbeat may give the old standby, ... an erratic heartbeat known as atrial fibrillation are at increased ... such as a blood clot. For this reason, they have ...
... release is available in French . , ROCKVILLE, ... Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a ... (TB) vaccine that involves people living with the human immunodeficiency ... sites in Senegal and South Africa with primary funding support ...
Cached Medicine News:Health News:Alcohol consumption in relation to acute pancreatitis 2Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 3Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 4Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 2Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 3
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: